Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$84,079.00-0.40%ETH$2,693.15+0.06%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
AL

NASDAQ · ALKS

Alkermes plc

Healthcare · Biotechnology

$40.79

Up+$0.06 (+0.15%)

Updated Sep 25, 2026, 11:31 PM

SID Score

6.4/10

Composite research score

Smart Money

62/100

Neutral

Market cap
4.97B
P/E ratio
20.51
Dividend yield
0.00%
52-week range
$27.00 – $55.67
Volume
2.84M
Avg. volume
1.92M

Price performance

ALKS price history

1M range · 20 trading sessions · Daily adjusted prices

ALKS closed at $40.79 after 20 trading sessions, down 16.58% for the selected period.

Last close
$40.79
Period change
-16.58%
Period low
$40.79
Period high
$48.90
Daily close
View OHLC price history
ALKS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 24, 2026$42.55$42.55$40.59$40.792.84M
Sep 23, 2026$43.20$43.62$41.23$42.132.48M
Sep 22, 2026$44.39$44.53$43.08$43.292.31M
Sep 21, 2026$44.27$44.79$43.11$44.183.73M
Sep 18, 2026$46.51$46.53$43.27$43.396.94M
Sep 17, 2026$47.10$47.397$46.41$46.711.42M
Sep 16, 2026$46.64$47.26$45.785$46.071.85M
Sep 15, 2026$45.73$46.14$44.63$46.032.15M
Sep 14, 2026$46.60$46.60$45.66$45.832.03M
Sep 11, 2026$46.75$46.75$45.73$45.971.28M
Sep 10, 2026$44.98$46.11$44.75$46.111.19M
Sep 9, 2026$45.24$45.605$44.72$45.401.44M
Sep 8, 2026$45.20$46.53$44.63$45.491.36M
Sep 4, 2026$46.14$46.93$45.80$46.101.06M
Sep 3, 2026$48.01$48.29$46.71$46.88974.51K
Sep 2, 2026$47.70$48.735$46.68$47.721.57M
Sep 1, 2026$47.00$47.335$46.65$47.201.35M
Aug 31, 2026$47.25$47.56$46.46$46.991.44M
Aug 28, 2026$48.82$48.82$47.2501$47.411.43M
Aug 27, 2026$48.72$49.33$48.10$48.902.12M

Latest ALKS news

The latest Smart Investors Daily articles mentioning ALKS.

Stock researchCompany · Overview

ALKS research

Overview

Company profile and research snapshot.

Company profile

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$46.00
Implied upside
—
Analysts
23
ALKS recent ratings
DateFirmRatingTarget
Sep 24, 2026Goldman SachsNeutral—
Sep 22, 2026RBC CapitalOutperform—
Sep 22, 2026BairdOutperform—
Sep 21, 2026NeedhamBuy—
Jul 29, 2026JP MorganNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

DUBLIN, September 16, 2026--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations.

Yahoo · Sep 10, 2026

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

DUBLIN, September 10, 2026--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. Building on prior award cycles, the program will continue to accept applications related to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By